Postoperative Radiation of Patients With Breast Cancer in Extreme Hypofractionation.
Postoperative External Beam Whole Breast or Chest Wall Irradiation of Patients With Breast Cancer in Extreme Hypofractionation.
研究概览
地位
条件
详细说明
The focus of this phase 2-trial is set on feasibility as well as early and late toxicity rates. One possible disadvantage of extreme hypofractionation could be an increased rate of fibrosis within the irradiated region. Therefore, a closer look will be taken with this prospective trial.
In addition, we are planning an accompanying translational research program since hypofractionated schedules are suggested to be more immunogenic in breast cancer.
Secondary objectives therefore are: cosmetic outcome, local tumor control, quality of life, dynamic immune status, importance of tumor infiltrating immune cells, overall survival, disease-free survival, feasibility of breath-hold radiation technique.
研究类型
注册 (预期的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Histologically confirmed invasive breast cancer or ductal carcinoma in situ (DCIS)
- pT-category pT0-3
- complete resection (R0)
- Absence of distant metastasis (M0)
- Absence of contralateral breast cancer/ DCIS
- Karnofsky Performance Score ≥ 60%
- Age ≥ 18 years at time of study entry
- Written informed consent
Exclusion Criteria:
- All patients not fulfilling inclusion criteria
- Morbus Paget or pathological skin infiltration
- Earlier or synchronous breast cancer
- Pregnant or breast-feeding women
- Increased radiosensitivity or any genetic disposition for increased radiosensitivity, e.g. ataxia telangiectatica
- Judgement by the investigator that the patient is unlikely to comply with study procedures and requirements
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Incidence and grade of Treatment related adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0)
大体时间:08/2022 - 07/2035
|
Evaluation during treatment and at each follow-up visit up to 10 years
|
08/2022 - 07/2035
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Cosmetic results according to the Harvard-scale
大体时间:05/2022 - 04/2035
|
Clinical evaluation of the irradiated breast at each follow-up up to 10 years according to the Harvard-scale (patient's and physician's view)
|
05/2022 - 04/2035
|
In-breast recurrence rate
大体时间:05/2022 - 04/2035
|
Evaluation at each follow-up up to 10 years via regular examinations including mammography/ ultrasound
|
05/2022 - 04/2035
|
Quality of life during and after treatment using the patient-reported questionnaires EORTC QLQ-C30 and QLQ-BR23
大体时间:05/2022 - 04/2035
|
Evaluation of patient's quality of life from inclusion to each follow-up up to 10 years via standardized questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 and the breast-orientated QLQ-BR23
|
05/2022 - 04/2035
|
Immune status analysis: Immunophenotyping using peripheral blood at several time points
大体时间:05/2022 - 04/2027
|
Withdrawals of whole blood (plasma and serum) before the first irradiation until one year after the treatment.
Immunophenotyping by a modular multicolor flow cytometry-based method.
Furthermore, whole exome sequencing/RNASeq on already obtained tissue from the breast surgery.
|
05/2022 - 04/2027
|
Overall survival
大体时间:05/2022 - 04/2035
|
Evaluation at each follow-up up to 10 years
|
05/2022 - 04/2035
|
Evaluation of feasibility of breath-hold radiation technique throughout the treatment time
大体时间:05/2022 - 04/2025
|
Evaluation of patient's capability to follow breathing commandos during planning-CT scan and each application of radiotherapy
|
05/2022 - 04/2025
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.